Ariana Pharma

🌟 A New Chapter for Ariana Pharma 🌟 Ariana Pharma is proud to welcome Dr. Pascale Bouillé as our new CEO! Under her leadership, Ariana Pharma embraces a bold new tagline: “Drug Development, Re-Imagined.” This reflects our position as a strategic partner, ready to tackle the most complex challenges in drug development with transformative solutions. 💬 In Dr. Bouillé's words: "By reimagining drug development, we strive to inspire a paradigm shift, going beyond traditional probability- and statistics-based approaches. At Ariana, we deliver results grounded in logic-based rules, ensuring our analyses meet—and often exceed—your needs. This vision reflects our unwavering commitment to pushing the boundaries of innovation and delivering tangible, impactful outcomes." https://lnkd.in/gh-f8i9T Pascale Bouillé

Cela fait maintenant 2 ans que j’accompagne Ariana Pharma, une entreprise pionnière dans l’xIA au service de la santé… un challenge où savoir mieux analyser les données, meme des petites cohortes de données, fait toute la difference. Et quand on lit cet article sur les limites d’autres formes d’IA, Mohammad Afshar était bien un visionnaire il y a maintenant plus de 20 ans 😊 #onsebouge https://lnkd.in/eq-h845A

𝗛𝗼𝘄 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗜𝘀 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗶𝗸𝗲 𝗛𝗟𝗛. Hemophagocytic Lymphohistiocytosis (HLH) is a rare hematologic disorder that can affect both children and adults. While optimal treatment remains a subject of debate, cytokine-targeted therapies have shown promise. At 𝗔𝗿𝗶𝗮𝗻𝗮, we wanted to evaluate the impact on the healthcare system of HLH, taking advantage of available public data and the capabilities of our 𝗞𝗘𝗠® 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. 📊 Key findings from our analysis: ▪ Despite a limited patient population, 𝗛𝗟𝗛 ranks within the 𝘁𝗼𝗽 𝟱% 𝗼𝗳 𝗰𝗼𝘀𝘁𝗹𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 in terms of 𝗮𝘃𝗲𝗿𝗮𝗴𝗲 hospital admission costs. ▪ 𝗧𝗼𝘁𝗮𝗹 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗼𝘂𝘁𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗼𝘀𝘁𝘀 between 2008-2024 are estimated to exceed €𝟭𝗠. ▪ 𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝗮𝗱𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝘁𝗿𝗲𝗻𝗱𝘀 show a consistent increase in HLH diagnoses, with two structural shifts in 2016 and 2021, likely tied to changes in diagnostic guidelines. ▪ The 𝗮𝗴𝗲 𝗼𝗳 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 is shifting, with more pediatric patients being diagnosed, while the incidence among adults remains stable. ▪ Main 𝗰𝗼𝗺𝗼𝗿𝗯𝗶𝗱𝗶𝘁𝗶𝗲𝘀 are fever, anemia, hemato/lymphoid neoplasms, and most prescribed 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 are injectable immunoglobulins, cyclosporin, desmopressin, mycophenolic acid and tacrolimus. The Ariana team is committed to contribute to the development of treatments against rare diseases such as HLH, by increasing the probability of success of drug development and identifying the best treatment sequences, leveraging the capabilities of the 𝗞𝗘𝗠® 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Together, we can improve outcomes for patients battling rare diseases. Pascale Bouillé - Frédéric Parmentier - Thomas TURCAT - Hichem C. - David Morley #HLH #HealthcareInnovation #RareDiseases #Ariana #KEMplatform #CytokineTherapies #MedicalResearch #Pharma #HealthcareData #RWE

This is one of the most powerful reports (https://lnkd.in/eafUcKqi) about the value of personalized medicine in the treatment of Alzheimer's disease. Anavex reports superior therapeutic response in their Phase 2/3 blarcamesine trial results for the wild type SIGMAR1 Q2P patient population. The superior therapeutic response for wild type SIGMA Q2P populations was originally identified from earlier Anavex clinical data in collaboration with Ariana Pharma.: Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, Kaufmann WE, Missling CU, Afshar M. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy. Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimers Dement (N Y). 2020 Apr 19;6(1):e12013. doi: 10.1002/trc2.12013. PMID: 32318621; PMCID: PMC7167374. It can be a long road for the evidentiary standards of personalized medicine to be met. Sometimes, however, we do get there.

We’re thrilled to announce a strategic alliance between CorpusAnalytiX and Ariana Pharma to harness the power of #AI and #realworld healthcare data to accelerate drug development. This partnership combines our expertise in advanced data analytics to drive more efficient and effective healthcare solutions. Together, we’re committed to enhancing clinical development and market access for the benefit of sponsors, healthcare providers, and—most importantly—patients. https://lnkd.in/eXc5XPxr Frédéric Parmentier - Ansh Tandon - Thomas TURCAT

We are excited to share the great work presented by Professor Yoram Bouhnik and his team from Institut des MICI at #uegweek2024, featuring a poster on our innovative #AI project applied to #IBD. This project, involving Pablo Iriso, Frédéric Parmentier, and Chaima Romdhane, is a significant step towards better predicting therapeutic responses and optimizing care for patients with IBD. A big thank you to all our partners for their dedication to advancing personalized and effective medicine! Together, we are making strides in improving patient outcomes. #AI #PersonalizedMedicine #IBD #Collaboration #Innovation

Thank you SEQENS for the invitation to participate in your annual seminar and the insightful discussion on how Big Data and AI are transforming healthcare. It was a privilege for our Vice President of Data Science, Frédéric Parmentier, to join such an esteemed panel, moderated by Professor Antoine Tesniere, alongside Professor Guillaume Assié and Lucia Cinque. Stay tuned for the upcoming podcast on "Séquence," where the full discussion will be available. #AI #xAI #AIinHealthcare #Seqens #ArianaPharma #BigData

It is with profound sadness that we announce the passing of our founder and CEO, Dr. Mohammad Afshar, on August 8, 2024. Dr. Afshar was a visionary leader but also a physician, researcher, entrepreneur, and pioneer in the field of #AI and healthcare. His legacy will continue to inspire us all, and he will be deeply missed. For over two decades, Mohammad dedicated his boundless energy and expertise to advancing artificial intelligence in healthcare, particularly in the realm of clinical trials, both in France and the USA. He was deeply passionate about sharing his scientific and medical insights, and he tirelessly advocated for the role of entrepreneurship in shaping the future of medicine. Known for his quick thinking, stimulating conversations, and visionary foresight, Mohammad was always several steps ahead in his field. Today, the world of innovative entrepreneurship has lost one of its most influential champions. Mohammad's unwavering commitment to pushing the boundaries of medical innovation for the betterment of patients will continue to drive us forward. He built a strong, capable team at Ariana Pharma that, inspired by his legacy, will carry on his mission of harnessing AI to revolutionize medicine and securing Ariana Pharma's place as a global leader. In recent months, as Mohammad had stepped back from daily operations, Ariana Pharma established a robust organizational structure to ensure seamless continuity for our clients and partners. This team is led by Pascale Bouillé, CEO, alongside the leadership team: Thomas TURCAT as COO, Hichem Chakroun as SVP of Clinical Development, Frédéric Parmentier as VP of Data Science, Federico Goodsaid as SVP of Regulatory Affairs, and David Morley as Chief Product Officer in charge of RWE. Mohammad was married and the father of four children. His family and Ariana will honour his memory at a commemorative celebration to be held in Paris in early September.

To conclude our series celebrating Ariana's 20-year anniversary, discover the achievements that make us proud. Thomas TURCAT Federico Goodsaid Hichem Chakroun Kia Motesharei Mohammad Afshar